title: Growth hormone secretion and circulating insulin-like growth factor-I (IGF-I) and IGF binding protein-3 concentrations in children with sickle cell disease.
abstract: Impaired growth involving both height and weight accompanying sickle cell disease (SCD) poses diagnostic and therapeutic problems. We undertook this study to test the hypothesis that this impaired growth is associated with abnormalities of the growth hormone (GH)/insulin-like growth factor-I (IGF-I)/IGF binding protein-3 (IGFBP-3) axis in 21 children with SCD and that SCD is associated with GH resistance. Nine of 21 children with SCD had a defective GH response to both clonidine and glucagon provocation (peak < 10 micrograms/L); these children differed from the 12 others in having slower linear growth velocity (GV and GVSDS), lower circulating concentrations of IGF-I and IGFBP-3, and either partial or complete empty sellae in computed tomographic scans of the hypothalamic-pituitary area. In this group of patients with SCD, it appears that defective GH secretion and consequent low IGF-I production are the major etiological factors causing the slow growth. The two groups with SCD did not differ significantly in dietary intake, body mass index (BMI), midarm circumferences, skinfold thickness, serum albumin concentration, or intestinal absorption of D-xylose. A single injection of GH produced a smaller increase in circulating IGF-I in children with SCD with or without defective GH secretion versus 10 age-matched children with idiopathic short stature (ISS) and 11 children with isolated GH deficiency (GHD), suggesting partial GH resistance in the SCD group. The presence of defective GH secretion, decreased IGF-I synthesis, and partial resistance to GH in short children with SCD suggests that treatment with IGF-I may be superior to GH therapy for improving growth.
authors.affiliation: Department of Pediatrics, Royal Hospital, Muscat, Oman.
authors.forename: A T
authors.initials: AT
authors.lastname: Soliman
authors.forename: N
authors.initials: N
authors.lastname: el Banna
authors.forename: I
authors.initials: I
authors.lastname: alSalmi
authors.forename: V
authors.initials: V
authors.lastname: De Silva
authors.forename: A
authors.initials: A
authors.lastname: Craig
authors.forename: M
authors.initials: M
authors.lastname: Asfour
mesh_terms: D000316:Adrenergic alpha-Agonists; D002648:Child; D002675:Child, Preschool; D003000:Clonidine; D015331:Cohort Studies; D005293:Ferritins / Q000097:blood; D005934:Glucagon; D006130:Growth Disorders / Q000097:blood* / Q000150:complications / Q000503:physiopathology; D006450:Hemoglobin SC Disease / Q000097:blood* / Q000150:complications / Q000503:physiopathology; D019382:Human Growth Hormone / Q000008:administration & dosage / Q000097:blood / Q000172:deficiency / Q000378:metabolism*; D006801:Humans; D007279:Injections, Subcutaneous; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood*; D007334:Insulin-Like Growth Factor I / Q000032:analysis*; D011863:Radioimmunoassay; D011994:Recombinant Proteins / Q000008:administration & dosage
chemical_list: D000316:Adrenergic alpha-Agonists; D018972:Insulin-Like Growth Factor Binding Protein 3; D011994:Recombinant Proteins; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I; D005293:Ferritins; D005934:Glucagon; D003000:Clonidine